Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy

While lenalidomide (LEN) is the standard of care for the lower-risk myelodysplastic syndromes (MDS) patients with deletion 5q, 35% will not respond to or do not tolerate the drug. Moreover, most of the patients will lose their response after a few years. Defining the outcome of patients with LEN fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Prebet, Thomas, Cluzeau, Thomas, Park, Sophie, Sekeres, Mikkael A., Germing, Ulrich, Ades, Lionel, Platzbecker, Uwe, Gotze, Katharina, Vey, Norbert, Oliva, Esther, Sugrue, Mary M., Bally, Cecile, Kelaidi, Charikleia, Al Ali, Najla, Fenaux, Pierre, Gore, Steven D., Komrokji, Rami
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669859/
https://www.ncbi.nlm.nih.gov/pubmed/29137233
http://dx.doi.org/10.18632/oncotarget.18477

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669859/
https://www.ncbi.nlm.nih.gov/pubmed/29137233
http://dx.doi.org/10.18632/oncotarget.18477

Ejemplares similares